Gianluigi Patelli1, Antonio Ranieri2, Aurelio Paganelli2, Giovanni Mauri3, Claudio Maurizio Pacella4. 1. Department of Interventional Radiology, Pesenti-Fenaroli Hospital-ASST Bergamo Est, 24022, Alzano Lombardo, Italy. 2. Department of Urology, Pesenti-Fenaroli Hospital-ASST Bergamo Est, 24022, Alzano Lombardo, Italy. 3. Department of Interventional Radiology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. giovanni.mauri@ieo.it. 4. Department of Diagnostic Imaging and Interventional Radiology, "Regina Apostolorum" Hospital, 00041, Alzano Lombardo, Italy.
Abstract
PURPOSE: To assess the feasibility and safety of transperineal laser ablation (TPLA) for treating benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Institutional review board approval was obtained for this prospective non-randomized trial. Eightteen patients (age 71.7 ± 9.4 years) with urinary symptoms secondary to BPH underwent TPLA under local anesthesia. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size. Primary endpoints were technical success and safety of TPLA. Secondary endpoints included operation time, ablation time, energy deployed, hospitalization time, catheterization time, and change in International Prostate Symptom Score (IPSS), Quality of Life (QoL), peak urinary flow rate (Q max), post-void residual (PVR), and prostatic volume at 3 months. χ 2 and Fisher exact tests were used. RESULTS: All procedures were technically successful. No complications occurred. Mean operation time was 43.3 ± 8.7 min, mean ablation time 15.9 ± 3.9 min, mean energy deployed 10,522 ± 3290.5 J, mean hospital stay 1.5 ± 0.4 days, and mean catheterization time 17.3 ± 10.0 days. At 3 months, IPSS improved from 21.9 to 10.7 (P < 0.001), QoL from 4.7 ± 0.6 to 2.1 ± 1.2 (P < 0.001), Q max from 7.6 to 13.3 mL/s (P = 0.001), PVR from 199.9 ± 147.3 to 81.5 ± 97.8 (P < 0.001), and mean prostate volume from 69.8 to 54.8 mL (P < 0.001). CONCLUSIONS: TPLA is feasible and safe in the treatment of BPH, providing significant clinical results at 3 months. LEVEL OF EVIDENCE: Case series, Level IV.
PURPOSE: To assess the feasibility and safety of transperineal laser ablation (TPLA) for treating benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Institutional review board approval was obtained for this prospective non-randomized trial. Eightteen patients (age 71.7 ± 9.4 years) with urinary symptoms secondary to BPH underwent TPLA under local anesthesia. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size. Primary endpoints were technical success and safety of TPLA. Secondary endpoints included operation time, ablation time, energy deployed, hospitalization time, catheterization time, and change in International Prostate Symptom Score (IPSS), Quality of Life (QoL), peak urinary flow rate (Q max), post-void residual (PVR), and prostatic volume at 3 months. χ 2 and Fisher exact tests were used. RESULTS: All procedures were technically successful. No complications occurred. Mean operation time was 43.3 ± 8.7 min, mean ablation time 15.9 ± 3.9 min, mean energy deployed 10,522 ± 3290.5 J, mean hospital stay 1.5 ± 0.4 days, and mean catheterization time 17.3 ± 10.0 days. At 3 months, IPSS improved from 21.9 to 10.7 (P < 0.001), QoL from 4.7 ± 0.6 to 2.1 ± 1.2 (P < 0.001), Q max from 7.6 to 13.3 mL/s (P = 0.001), PVR from 199.9 ± 147.3 to 81.5 ± 97.8 (P < 0.001), and mean prostate volume from 69.8 to 54.8 mL (P < 0.001). CONCLUSIONS: TPLA is feasible and safe in the treatment of BPH, providing significant clinical results at 3 months. LEVEL OF EVIDENCE: Case series, Level IV.
Authors: Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi Journal: Br J Radiol Date: 2018-01-17 Impact factor: 3.039
Authors: Nicola Frego; Alberto Saita; Paolo Casale; Pietro Diana; Roberto Contieri; Pier Paolo Avolio; Massimo Lazzeri; Rodolfo Hurle; Nicolò Maria Buffi; Giorgio Ferruccio Guazzoni; Giovanni Lughezzani Journal: World J Urol Date: 2021-04-03 Impact factor: 4.226
Authors: Rob A A van Kollenburg; Luigi A M J G van Riel; Paul R Bloemen; Jorg R Oddens; Theo M de Reijke; Harrie P Beerlage; Daniel Martijn de Bruin Journal: JMIR Res Protoc Date: 2020-01-21
Authors: Serena Carriero; Gianmarco Della Pepa; Lorenzo Monfardini; Renato Vitale; Duccio Rossi; Andrea Masperi; Giovanni Mauri Journal: Diagnostics (Basel) Date: 2021-03-19